Advice
in the absence of a submission from the holder of the marketing authorisation:
elinzanetant (Lynkuet®) is not recommended for use within NHSScotland.
Indication under review: treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.
Download detailed advice289KB (PDF)
Medicine details
- Medicine name:
- elinzanetant (Lynkuet)
- SMC ID:
- SMC2965
- Indication:
treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 August 2026